Ligand Pharmaceuticals Reports Q2 2026 Financial Results

What Happened
On August 6, 2026, Ligand Pharmaceuticals Incorporated announced its financial results for the three and six months ended June 30, 2026 via a press release furnished as Exhibit 99.1 to a Form 8-K (Item 2.02). The Form 8-K states the press release contains the company's quarterly results; the filing is signed by Andrew Reardon, Chief Legal Officer and Secretary, dated August 6, 2026. The Company notes that, under Form 8-K instructions, the furnished information is not “filed” for purposes of Section 18 of the Exchange Act.

Key Details

• Event: Press release announcing financial results furnished on Form 8-K (Item 2.02).
• Date filed: August 6, 2026.
• Reporting period: results cover the three and six months ended June 30, 2026.
• Exhibit: Press release furnished as Exhibit 99.1; filing includes the Form 8-K signature of Andrew Reardon.

Why It Matters
This filing provides Ligand’s latest quarterly results and is the primary source for updated earnings, revenue, cash flow and related operating information for the period ending June 30, 2026. Retail investors should read the furnished press release (Exhibit 99.1) for the specific financial figures and any commentary on performance or outlook, and note the disclosure is furnished (not “filed”) under SEC rules.